(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 124.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Liquidia's revenue in 2026 is $69,216,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $42,484,244,123, with the lowest LQDA revenue forecast at $21,943,740,632, and the highest LQDA revenue forecast at $63,357,070,359. On average, 8 Wall Street analysts forecast LQDA's revenue for 2027 to be $54,142,508,800, with the lowest LQDA revenue forecast at $34,365,825,649, and the highest LQDA revenue forecast at $72,455,927,926.
In 2028, LQDA is forecast to generate $67,865,176,288 in revenue, with the lowest revenue forecast at $54,566,176,802 and the highest revenue forecast at $90,388,306,837.